DUSA Stock Soars (DUSA)

NEW YORK ( TheStreet) -- Shares of DUSA Pharmaceuticals (Nasdaq: DUSA) have taken a tremendous swing upward. The stock is trading at $5.48 as of 10:31 a.m. ET, 21% above Wednesday's closing price of $4.53. Volume is at 637,952, 1.8 times the daily average of 355,100.

DUSA has a market cap of $117.8 million and is part of the health care sector and drugs industry. Shares are up 84.9% year to date as of the close of trading on Wednesday.

DUSA Pharmaceuticals, Inc., a vertically integrated dermatology company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions in the United States and internationally. The company has a P/E ratio of 43.8, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.

TheStreet Ratings rates DUSA as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full DUSA Ratings Report.

See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center.

Interested in other stocks that are soaring? Get free SMS text alerts sent to you when the action happens by texting SOAR to 95370 or select from multiple alert options.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing